<DOC>
	<DOC>NCT00915577</DOC>
	<brief_summary>Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.</brief_summary>
	<brief_title>Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid AVONEX® for 12 weeks prior to the Screening Visit. Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at Screening. Must be able to physically demonstrate use of the device and be able to selfadminister all injections. Must be English speaking. Must be able to understand and comply with the protocol. Abnormal screening or screening blood tests determined to be clinically significant by the investigator for: white blood count (WBC) or differential, platelet count, hemoglobin, serum creatinine, bilirubin, alanine transaminase (ALT) aspartate transaminase (AST), prothrombin time (PT). Known sensitivity to dry natural rubber. Treatment with other agents to treat MS symptoms or underlying disease as specified in the protocol. History of severe allergic or anaphylactic reactions. History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and aspirin that would preclude the use of at least one of these during the study. Serious local infection Other inclusion and exclusion criteria apply as per Biogen Idec Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>interferon beta-1a</keyword>
	<keyword>Avonex</keyword>
	<keyword>liquid Avonex</keyword>
</DOC>